home / stock / wuxay / wuxay quote
Last: | $5 |
---|---|
Change Percent: | -7.45% |
Open: | $5.05 |
Close: | $5 |
High: | $5.078 |
Low: | $5 |
Volume: | 8,476 |
Last Trade Date Time: | 05/10/2024 03:00:00 am |
Quotes are delayed by 15 to 20 minutes.
Last | Open | Close | High | Low | Volume | Date |
---|---|---|---|---|---|---|
$5 | $5.05 | $5 | $5.078 | $5 | 8,476 | 05-10-2024 |
$4.7 | $4.775 | $4.7 | $4.775 | $4.7 | 919 | 05-09-2024 |
$4.7044 | $4.692 | $4.7044 | $4.7044 | $4.65 | 2,990 | 05-08-2024 |
$4.72 | $4.785 | $4.72 | $4.785 | $4.7 | 3,807 | 05-07-2024 |
$4.9 | $4.855 | $4.9 | $5 | $4.855 | 3,179 | 05-06-2024 |
$4.77 | $4.86 | $4.77 | $4.86 | $4.72 | 5,213 | 05-03-2024 |
$5.07 | $4.81 | $5.07 | $5.07 | $4.81 | 5,432 | 05-02-2024 |
$4.475 | $0 | $4.475 | $0 | $0 | 56 | 05-01-2024 |
$4.475 | $4.45 | $4.475 | $4.475 | $4.45 | 5,929 | 04-30-2024 |
$4.45 | $4.45 | $4.45 | $4.615 | $4.45 | 3,570 | 04-29-2024 |
$4.41 | $4.53 | $4.41 | $4.53 | $4.405 | 27,447 | 04-26-2024 |
$4.235 | $4.14 | $4.235 | $4.235 | $4.14 | 3,135 | 04-25-2024 |
$4.33 | $4.34 | $4.33 | $4.34 | $4.305 | 11,062 | 04-24-2024 |
$4.36 | $4.305 | $4.36 | $4.42 | $4.305 | 3,094 | 04-23-2024 |
$4.29 | $4.29 | $4.29 | $4.29 | $4.29 | 2,223 | 04-22-2024 |
$4.2912 | $4.296 | $4.2912 | $4.296 | $4.2 | 1,268 | 04-19-2024 |
$4.52 | $4.36 | $4.52 | $4.52 | $4.36 | 1,557 | 04-18-2024 |
$4.52 | $4.41 | $4.52 | $4.52 | $4.41 | 1,691 | 04-17-2024 |
$4.1 | $4.29 | $4.1 | $4.29 | $4.1 | 6,874 | 04-16-2024 |
$4.35 | $4.35 | $4.35 | $4.4512 | $4.35 | 4,044 | 04-15-2024 |
News, Short Squeeze, Breakout and More Instantly...
Wuxi AppTec Co. Ltd. ADR Company Name:
WUXAY Stock Symbol:
OTCMKTS Market:
WuXi AppTec Achieved First Quarter 2024 Target Despite External Challenges, Maintaining Stable Operations PR Newswire Revenue Reached RMB7,982 Million ; Excluding COVID-19 Commercial Projects, Down 1.8% Net Profit Attributable to the Owners of the Company Reached...
WuXi AppTec Revenue Surpassed RMB40 Billion in 2023, and Adjusted Non-IFRS Net Profit Exceeded RMB10 Billion for the First Time PR Newswire Revenue Up 2.5% Year-over-Year to RMB40,341 Million ; Excluding COVID-19 Commercial Projects, Up 25.6% Net Profit Attributa...
WuXi Advanced Therapies Receives FDA Approval to Manufacture Iovance's AMTAGVI™ (lifileucel) for Advanced Melanoma PR Newswire AMTAGVI is the first and only one-time, individualized T cell therapy to receive U.S. FDA approval for a solid tumor cancer. ...